Market Research Report
Multiple Sclerosis Market Insight, Epidemiology and Market Forecast -2032
|Multiple Sclerosis Market Insight, Epidemiology and Market Forecast -2032|
DelveInsight Business Research LLP
Content info: 276 Pages
Delivery time: 2-10 business days
DelveInsight's 'Multiple Sclerosis (MS)-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Multiple Sclerosis (MS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Multiple Sclerosis (MS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Multiple Sclerosis (MS) symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Multiple Sclerosis (MS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, body's own immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.
The damaged myelin forms scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted.
People with Multiple Sclerosis (MS) generally develop symptoms in their late 20s, experiencing visual and sensory disturbances, limb weakness, gait problems and bladder and bowel syndromes. Initially, they may have partial recovery, but over time they develop progressive disability.
Multiple Sclerosis affected individuals may experience a variety of symptoms, physically, emotionally, mentally and psychologically. The severity and types of symptoms differ among the individuals; thus symptoms differ among different people.
There are four major categories in Multiple Sclerosis. These are: Relapsing-Remitting Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis, Primary-Progressive Multiple Sclerosis, and Progressive-Relapsing Multiple Sclerosis.
There is no single test used to diagnose Multiple Sclerosis. The disease is confirmed when symptoms and signs develop and are related to different parts of the nervous system at more than one interval in time and after other alternative diagnoses have been excluded.
Doctors use different tests to rule out or confirm the diagnosis. In addition to complete medical history, physical examination, and a detailed neurological examination, a doctor may recommend: MRI scans of the brain and spinal cord to look for the characteristic lesions of MS. A special dye or contrast agent may be injected into a vein to enhance brain images of the active MS lesions.
Lumbar puncture (sometimes called a spinal tap) to obtain a sample of cerebrospinal fluid and examine it for proteins and inflammatory cells associated with the disease. Spinal tap analysis also can rule out diseases that may look like MS.
It covers the details of conventional and current medical therapies and diagnosis available in the Multiple Sclerosis (MS) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Multiple Sclerosis (MS) market report gives a thorough understanding of Multiple Sclerosis (MS) symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Multiple Sclerosis (MS) treatment algorithms and treatment guidelines in the US, Europe, and Japan.
The epidemiology division's Multiple Sclerosis (MS) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Multiple Sclerosis (MS) epidemiology segmented as the Total Prevalent Cases of Multiple Sclerosis (MS), Sub-type Specific Prevalent cases of Multiple Sclerosis (MS), Gender Specific Prevalence of Multiple Sclerosis (MS). The report includes the prevalent Multiple Sclerosis (MS) scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Multiple Sclerosis (MS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM prevalent cases of Multiple Sclerosis (MS) were 1,265000 in 2020.
The drug chapter segment of the Multiple Sclerosis (MS) report encloses the detailed analysis of Multiple Sclerosis (MS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Multiple Sclerosis (MS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
In March 2020, the company initiated a Phase II, Multi-center, randomized, double-blind, placebo-controlled, two-arm parallel design study of NeuroVax vs. Incomplete Freund's Adjuvant (IFA) placebo with Secondary Progressive SPMS. The study is estimated to complete on March 2023, with an estimated enrollment of 200 participants.
The Multiple Sclerosis (MS) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Multiple Sclerosis (MS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Multiple Sclerosis (MS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Multiple Sclerosis (MS) market in 7MM is expected to change in the study period 2019-2032.
This section includes a glimpse of the Multiple Sclerosis (MS) market in 7MM. The market size of Multiple Sclerosis (MS) in the seven major markets was found to be USD 22,381 million in 2020.
This section provides a total of Multiple Sclerosis (MS) market size and market size by therapies in the United States.
The United States accounts for the highest Multiple Sclerosis (MS) market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The total Multiple Sclerosis (MS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Multiple Sclerosis (MS) market size and market size by therapies in Japan are also mentioned.
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Multiple Sclerosis (MS) market uptake by drugs, patient uptake by therapies, and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Multiple Sclerosis (MS) key players involved in developing targeted therapeutics.
Major players: NeuroVax (Immune Response BioPharma Inc.), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), Ublituximab (TG Therapeutics, Inc.), ALKS 8700 (Alkermes/Biogen), and Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical), and others are being assessed as potential therapies to be available in the market in the coming future.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Multiple Sclerosis (MS) emerging therapies.
To keep up with current market trends, we take KOLs and SME's opinion working on Multiple Sclerosis (MS) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Multiple Sclerosis (MS) market trends. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.
We perform a Competitive and Market Intelligence analysis of the Multiple Sclerosis (MS) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.